November 4, 2009 (Philadelphia, Pennsylvania) — Multidrug-resistant (MDR) Acinetobacter baumannii (ACBA) is a persistent threat to hospitalized patients, whether the infection is acquired in the ...

A research team has discovered a fundamental mechanism that helps the dreaded hospital pathogen Acinetobacter baumannii to survive. This mechanism explains why the pathogen is difficult to eradicate ...

Acinetobacter baumannii represents a formidable nosocomial pathogen, largely due to its rapid acquisition of multidrug resistance and its capacity to cause severe infections. This Gram‐negative ...

New research has shown that a lack of dietary zinc can boost the chances of a lung infection caused by Acinetobacter baumannii bacteria; these pathogens are a major reason why people on ventilators ...

Researchers discovered an unexpected link between zinc deficiency, the pro-inflammatory cytokine interleukin-13 (IL-13), and Acinetobacter baumannii lung infection and demonstrated that blocking IL-13 ...

XACDURO is a new FDA-approved treatment used to fight against HABP/VABP infections caused by isolates of Acinetobacter baumannii-calcoaceticus complex, which can include those resistant to carbapenems ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved sulbactam-durlobactam for nosocomial pneumonia caused by drug-resistant Acinetobacter baumannii ...

Credit: Getty Images. A PDUFA target date of May 29, 2023 has been set for the application. The Food and Drug Administration’s (FDA) Antimicrobial Drugs Advisory Committee unanimously voted 12-0 in ...

Sulbactam-durlobactam is the first pathogen-targeted therapy under investigation for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by ...

In an effort to illustrate that genomic surveillance can build the foundation for scaleable precision phage therapy, an international collaboration analyzed the genomes of over 15,000 cases of ...